Jump to: navigation, search
Clinical data
AHFS/Drugs.comInternational Drug Names
Routes of
Oral, IM
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Elimination half-life3–5 hours
CAS Number
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Molar mass354.46 g/mol
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

WikiDoc Resources for Sultopride


Most recent articles on Sultopride

Most cited articles on Sultopride

Review articles on Sultopride

Articles on Sultopride in N Eng J Med, Lancet, BMJ


Powerpoint slides on Sultopride

Images of Sultopride

Photos of Sultopride

Podcasts & MP3s on Sultopride

Videos on Sultopride

Evidence Based Medicine

Cochrane Collaboration on Sultopride

Bandolier on Sultopride

TRIP on Sultopride

Clinical Trials

Ongoing Trials on Sultopride at Clinical

Trial results on Sultopride

Clinical Trials on Sultopride at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Sultopride

NICE Guidance on Sultopride


FDA on Sultopride

CDC on Sultopride


Books on Sultopride


Sultopride in the news

Be alerted to news on Sultopride

News trends on Sultopride


Blogs on Sultopride


Definitions of Sultopride

Patient Resources / Community

Patient resources on Sultopride

Discussion groups on Sultopride

Patient Handouts on Sultopride

Directions to Hospitals Treating Sultopride

Risk calculators and risk factors for Sultopride

Healthcare Provider Resources

Symptoms of Sultopride

Causes & Risk Factors for Sultopride

Diagnostic studies for Sultopride

Treatment of Sultopride

Continuing Medical Education (CME)

CME Programs on Sultopride


Sultopride en Espanol

Sultopride en Francais


Sultopride in the Marketplace

Patents on Sultopride

Experimental / Informatics

List of terms related to Sultopride

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Sultopride (Barnetil, Barnotil, Topral) is an atypical antipsychotic of the benzamide chemical class used in Europe, Japan, and Hong Kong for the treatment of schizophrenia.[1][2][3] It was launched by Sanofi-Aventis in 1976.[1] Sultopride acts as a selective D2 and D3 receptor antagonist.[4] It has also been shown to have clinically relevant affinity for the GHB receptor as well, a property it shares in common with amisulpride and sulpiride.[5]


  1. 1.0 1.1 José Miguel Vela; Helmut Buschmann; Jörg Holenz; Antonio Párraga; Antoni Torrens (2007). Antidepressants, Antipsychotics, Anxiolytics: From Chemistry and Pharmacology to Clinical Application. Weinheim: Wiley-VCH. ISBN 3-527-31058-4.
  2. Swiss Pharmaceutical Society (2000). Index Nominum 2000: International Drug Directory (Book with CD-ROM). Boca Raton: Medpharm Scientific Publishers. ISBN 3-88763-075-0.
  3. European Drug Index, 4th Edition. Boca Raton: CRC Press. 1998. ISBN 3-7692-2114-1.
  4. Burstein, E. S.; Ma, J; Wong, S; Gao, Y; Pham, E; Knapp, AE; Nash, NR; Olsson, R; Davis, RE (2005). "Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identification of the clozapine metabolite N-desmethylclozapine as a D2/D3 partial agonist". The Journal of Pharmacology and Experimental Therapeutics. 315 (3): 1278–87. doi:10.1124/jpet.105.092155. PMID 16135699.
  5. Maitre M, Ratomponirina C, Gobaille S, Hodé Y, Hechler V (1994). "Displacement of [3H] gamma-hydroxybutyrate binding by benzamide neuroleptics and prochlorperazine but not by other antipsychotics". Eur J Pharmacol. 256 (2): 211–4. doi:10.1016/0014-2999(94)90248-8. PMID 7914168.